Despite some recent improvements, millions of Americans still face significant barriers in affording GLP-1s. At the same time, many patients have found alternative, cheaper paths to get their hands on unregulated versions. Stephanie Sy reports for our series, GLP-1s: Reshaping America. Geoff Bennett